(Q56892124)

1

0 references

Aldo Morra

2

0 references

Diana Giannarelli

3

0 references

Giovanni Amato

4

0 references

Armida D'Incecco

5

0 references

Alessia Covre

6

0 references

Arthur Lewis

7

0 references

Marlon C Rebelatto

8

0 references

Riccardo Danielli

9

0 references

Maresa Altomonte

10

0 references

Anna Maria Di Giacomo

11

0 references

Michele Maio

The Lancet. Respiratory medicine

12

0 references

language of work or name

English

0 references

publication date

June 2018

0 references

published in

0 references

volume

6

0 references

issue

6

0 references

page(s)

451-460

0 references

cites work

Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Second line therapy in malignant pleural mesothelioma: A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Immune checkpoint inhibitors: new strategies to checkmate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

PD-1 and PD-L1 antibodies in cancer: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Clinical applications of PD-L1 bioassays for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2818%2930151-6

7 January 2021